BioSpace News Archive

The U.S. Food and Drug Administration announced the following actions taken in its ongoing response effort to the COVID-19 pandemic

Innovent Biologics, Inc. announced that the Company achieved first patient dosing in a pivotal Phase 2 registrational trial of parsaclisib, a novel and selective PI3Kδ inhibitor, in China.

Pharmazz, Inc. announced that sovateltide, an endothelin-B receptor agonist, significantly improved modified Rankin Scale of acute cerebral ischemic stroke patients when compared to patients receiving the best standard of care.

Transparency Market Research (TMR) has published a new report on the red biotechnology market for the forecast period of 2019–2027.

Transparency Market Research (TMR) has published a new report on the photobiostimulation devices market for the forecast period of 2019 to 2027.

Transparency Market Research PVT. LTD has published a new report titled, “Global Cryptococcosis Market”. According to the report, the global cryptococcosis market was valued at US$ 4.7 Bn in 2018 and is projected to expand at a CAGR of 4.3% from 2019 to 2027.

Purdue Pharma’s Avrio Health Donates $1.6 Million Worth of Betadine ® Antiseptic Products for Use by Frontline Healthcare Workers

Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its First Quarter 2020 Financial Results on Wednesday, May 6, 2020, at 4:30pm Eastern Time. The call will be webcast and may be accessed at Pacific Biosciences’ website at: https://investor.pacificbiosciences.com/ . Date: May 6, 2020 Time: 4:30pm ET Listen via Internet: https://investor.pacificbiosciences.com/ Toll-fre

Ethos Research & Development has been awarded a Phase 1 grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases under the auspices of the Small Business Innovation Research (SBIR) program and National Institutes of Health (NIH). The grant will be utilized to develop a urinary biomarker panel and softwa

Applied BioMath ( www.appliedbiomath.com ), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Xilio Therapeutics. Applied BioMath will continue work on semi-mechanistic pharmacokinetic/pharmacodynamic